clinical trial · NCT05147805
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Pulmonary Arterial HypertensionTreprostinil PalmitilPlacebo
brief summary
The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
started
Aug 24, 2022
primary completion
Mar 27, 2025
completion
Mar 27, 2025
last updated
Mar 30, 2026
official title
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol